title: Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa.
abstract: Glucose is the primary source of energy and a key substrate for most cells. Inhibition of cellular glucose uptake (the first step in its utilization) has, therefore, received attention as a potential therapeutic strategy to treat various unrelated diseases including malaria and cancers. For malaria, blood forms of parasites rely almost entirely on glycolysis for energy production and, without energy stores, they are dependent on the constant uptake of glucose. Plasmodium falciparum is the most dangerous human malarial parasite and its hexose transporter has been identified as being the major glucose transporter. In this review, recent progress regarding the validation and development of the P. falciparum hexose transporter as a drug target is described, highlighting the importance of robust target validation through both chemical and genetic methods. Therapeutic targeting potential of hexose transporters of other protozoan pathogens is also reviewed and discussed.
authors.affiliation: Centre for Infection, Division of Cellular and Molecular Medicine, St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK. kslavic@sgul.ac.uk
authors.forename: Ksenija
authors.initials: K
authors.lastname: Slavic
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Krishna
authors.forename: Elvira T
authors.initials: ET
authors.lastname: Derbyshire
authors.forename: Henry M
authors.initials: HM
authors.lastname: Staines
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D050260:Carbohydrate Metabolism; D055808:Drug Discovery; D006801:Humans; D009004:Monosaccharide Transport Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000962:Antimalarials; D009004:Monosaccharide Transport Proteins